Both Xencor Inc. (NASDAQ:XNCR) and iBio Inc. (NYSEAMERICAN:IBIO) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor Inc.	48.75M	41.57	55.28M	-0.77	0.00
iBio Inc.	N/A	47.25	16.94M	-1.39	0.00

In table 1 we can see Xencor Inc. and iBio Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both businesses.

	Net Margins	Return on Equity	Return on Assets
Xencor Inc.	-113.39%	-13.4%	-11.8%
iBio Inc.	0.00%	-164.6%	-44.6%

Risk & Volatility

A 1.8 beta indicates that Xencor Inc. is 80.00% more volatile compared to Standard & Poor’s 500. iBio Inc.’s 66.00% less volatile than Standard & Poor’s 500 volatility due to the stock’s 0.34 beta.

Analyst Ratings

The table shown features the ratings and recommendations for Xencor Inc. and iBio Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Xencor Inc.	0	0	2	3.00
iBio Inc.	0	0	0	0.00

Xencor Inc.’s upside potential currently stands at 38.73% and an $50 consensus target price.

Institutional & Insider Ownership

Institutional investors owned 84.1% of Xencor Inc. shares and 6.7% of iBio Inc. shares. Insiders owned 0.9% of Xencor Inc. shares. Comparatively, iBio Inc. has 45.3% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Xencor Inc.	-10.69%	-10%	-6.5%	-10.13%	68.55%	71.17%
iBio Inc.	-7.69%	-8.86%	-13.25%	-45.86%	-52%	-59.35%

For the past year Xencor Inc. has 71.17% stronger performance while iBio Inc. has -59.35% weaker performance.

Summary

On 7 of the 10 factors Xencor Inc. beats iBio Inc.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The companyÂ’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies. Its product candidates also comprise XmAb5574/MOR208, which is in Phase II clinical trials for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia; and XmAb13551 that is in preclinical trials used for the treatment of multiple myeloma. The company has license agreement with Amgen Inc. and MorphoSys Ag to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

iBio, Inc., a biotechnology company, focuses on developing and commercializing pharmaceutical product applications using its platform in the United States and internationally. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has license and collaboration agreements with Caliber Biotherapeutics LLC and Fiocruz; and collaboration agreements with the A & M University System, AzarGen Biotechnologies (Pty) Ltd, Fraunhofer Center for Molecular Biotechnology, and Theoremdx, Inc. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is based in New York, New York.